Pfizer Limited

PFIZER

INE182A01018

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:48 2024-04-26 am EDT			5-day change	1st Jan Change
4,194 ^INR	+1.22%		+1.54%	-1.76%

Apr. 02	Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer	CI
Apr. 02	Pfizer Limited Appoints Amit Agarwal as Whole-Time Director, Designated as Executive Director Finance	CI

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

February 09, 2024 at 04:41 am EST

Pfizer Limited informed that Mr. Satyen Amin, Lead - Market Access has tendered his resignation from employment of the Company with effect from March 31, 2024, to pursue an opportunity outside Pfizer Limited. Mr. Satyen Amin shall accordingly cease to be a Senior Management Personnel effective the said date.

Latest news about Pfizer Limited

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer	Apr. 02	CI
Pfizer Limited Appoints Amit Agarwal as Whole-Time Director, Designated as Executive Director Finance	Apr. 02	CI
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	Mar. 28	CI
Pfizer Limited Receives an Order from Joint Commissioner of State Tax Basis the GST Audit Conducted for Uttar Pradesh State for the Financial Year 2018-19	Mar. 22	CI
Pfizer Limited Receives an Order from Deputy Commissioner of State Tax Basis the GST Audit Conducted for the Financial Year 2018-19	Mar. 19	CI
Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024	Feb. 09	CI
Pfizer Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 09	CI
Pfizer Ltd. Names CFO	Jan. 21	MT
Pfizer CFO Retires	Dec. 01	MT
Pfizer Limited Announces Retirement of Mr. Milind Patil as Chief Financial Officer	Nov. 30	CI
Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023	Nov. 16	CI
Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023	Nov. 13	CI
Pfizer Sees Sharp Fall in Fiscal Q2 Net Profit	23-10-30	MT
Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors	23-10-28	CI
Pfizer Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-28	CI
Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead	23-09-06	CI
Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023	23-08-21	CI
Pfizer Limited Announces Change in Management, Effective September 1, 2023	23-08-18	CI
Seagen's breast cancer therapy meets main goal in late-stage study	23-08-16	RE
Pfizer Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023	23-07-27	CI
Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm Injections	23-05-18	CI
Pfizer Posts Higher Fiscal Q4 Net Profit	23-05-16	MT
Pfizer's India unit posts 3% rise in Q4 profit	23-05-15	RE
Pfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023	23-05-15	CI

Chart Pfizer Limited

Duration

Period

More charts

Company Profile

Pfizer Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company has its own manufacturing facility at Goa. The Company has various independent contract/third party manufacturers based across India. Its product portfolio includes vaccine, anti-infectives, cardiac, pain, maternal nutrition, gastrointestinal, contraceptives, anti-inflammatory, nutrition and immunity, and respiratory. The Company's vaccine business is focused on Prevenar 13, a pneumococcal conjugate vaccine that is administered to infants who are six weeks and older as part of primary vaccination, toddlers, adolescents, adults, and elderly population. Its inflammation and immunology portfolio includes two advanced therapies, which cater to patients suffering from diseases related to chronic immune system such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis and ulcerative colitis.

Sector

Pharmaceuticals

Calendar

2024-05-28 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Pfizer Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER LIMITED	-1.76%	2.3B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Pfizer Limited

Equities

PFIZER

INE182A01018

Pharmaceuticals

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Latest news about Pfizer Limited

Chart Pfizer Limited

Company Profile

Income Statement Evolution

Ratings for Pfizer Limited

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals